u/Standard-Pain-3405

▲ 12 r/ASX+1 crossposts

EchoIQ (ASX: EIQ) — Pro Medicus backed them with up to $20M. FDA decision on EchoSolv HF still pending. DD + thoughts inside.

Been watching this one closely and wanted to put the pieces together for anyone else tracking it.

The Pro Medicus deal (25 June 2026)-

Pro Medicus (ASX: PME) — one of the most respected names in health imaging software globally — signed a binding Heads of Agreement with EchoIQ covering:

•	An initial A$10M investment via secured convertible notes, with an option for a further A$10M if EchoIQ’s EchoSolv HF gets FDA clearance

•	Notes carry 12.5% interest, convert at a A$1.05 cap (or lower via 5-day VWAP), plus 0.75 options per note struck at A$1.35

•	PME becomes a US reseller of EchoSolv, giving EIQ access to PME’s existing network of US health systems, academic medical centres, and enterprise healthcare customers via Visage 7 Cardiology

•	Definitive legal agreements were due within 20 business days of signing — worth checking ASX announcements for confirmation this has been finalised  

What’s happened since

•	1 July: EchoIQ raised A$110M at A$1.45/share from institutional and retail investors — company says it’s now fully funded for US commercialisation

•	New CFO and a structural-heart specialist added to the clinical network

•	Stock has run from well under A$1 to the \~A$1.60 range on the back of all this

The pending catalyst-

The big one is FDA clearance for EchoSolv HF (heart failure algorithm) — this is what unlocks PME’s second A$10M tranche and is the main re-rating catalyst people are watching for. Per the company’s own announcement, clearance “remains subject to regulatory review” with no guaranteed timeframe.

My take-

The PME tie-up is a real validation — PME doesn’t have to do deals like this, and getting picked as a reseller partner plus an equity backer says something about how they view EchoSolv’s clinical utility. Combined with the funding round, EIQ looks well capitalised to execute regardless of near-term dilution from the notes/options.

That said — worth being clear-eyed:
• FDA clearance is not guaranteed and timing on these things slips often
• Even with clearance, reimbursement (CPT coding) and actual uptake through PME’s channel are separate unproven steps
• The reseller agreement itself was still pending “definitive legal documentation” as of the HOA signing
• Stock has already re-rated a long way — a lot of good news may already be priced in
This is a binary, catalyst-driven microcap, not a “set and forget.” Sizing accordingly matters.

Disclosure: I hold EIQ. Not financial advice — do your own research.

reddit.com
u/Standard-Pain-3405 — 5 days ago
▲ 29 r/ASX_Bets+1 crossposts

What happened with Wisetech WTC ASX? Why it’s going down? I am not seeing any news?

WiseTech (WTC) is getting smacked again, down around $4 as I type this and sitting right on its lows. I’ve checked the ASX announcements page, company news, broker notes — nothing fresh that I can find to explain a move this big.

Only things I can think of: the hawkish Fed read-through hammering long-duration software (WTC always seems to move ~3x the tech index on red days), lingering nerves after the CargoWise outage last week, or just passive/index flow near the lows.

Am I missing an announcement or a downgrade? Anyone seeing something I’m not? FY26 result isn’t until late August so it shouldn’t be earnings-related.

reddit.com
u/Standard-Pain-3405 — 15 days ago
▲ 46 r/ASX_Bets+1 crossposts

CSL just dropped a guidance cut, $5B impairment AND a missing CEO in one announcement — and the stock is somehow up. Let’s talk about it.

For those who missed it, CSL released their Interim CEO 90 Day Review this morning (11 May). Here’s the damage:
The guidance cut:
• FY26 revenue revised down to ~$15.2B (constant currency)
• NPATA cut to ~$3.1B — excluding restructuring and impairments (of course)
• ~$650M total revenue haircut driven by:
• US Immunoglobulin channel inventory normalisation (~$300M)
• China Albumin market value decline (~$200M)
• Middle East conflict + HEMGENIX disappointment + iron competition (~$150M)
The $5 billion impairment elephant in the room:
On top of the $1.5B already booked at 1H results, they’re flagging an additional ~$5B in non-cash pre-tax impairments across FY26/FY27. Primarily CSL Vifor intangibles. You know — the acquisition they paid ~$16B for in 2022 that has basically been a value destruction machine ever since.
Leadership vacuum:
• Still no permanent CEO
• CCO Andy Schmeltz is retiring for “personal reasons”
• Interim CEO Gordon Naylor will step down to Non-Executive Director once a permanent CEO is found
The bull case they’re pushing:
IG demand is genuinely growing mid-to-high single digits. PRIVIGEN IVIg share has ticked up from 19% to 21%. Transformation savings of $500M-$550M per annum targeted by FY28. Seqirus separation on track for 1 July.
My take:
The market may be down 3-4% today treating this as a “kitchen sink” moment. Maybe. But the recurring theme with CSL over the past 3 years is that every downgrade comes with “growth initiatives are working, benefits just take longer than expected.” That line is in today’s presentation verbatim.
Vifor was a $16B bet that isn’t paying off. The pipeline has had multiple Phase 3 failures. Invested capital grew faster than earnings for years. And now we’re supposed to trust a recovery timeline that won’t fully materialise until FY28 at the earliest — with no permanent CEO at the wheel.
For those holding from $200+: at what point does “long-term compounder” become “sunk cost”?
Full year results: 18 August 2026. That’s the next real catalyst.

reddit.com
u/Standard-Pain-3405 — 2 months ago